A Second Confirmatory, Events-Driven Phase 3 Trial of Revascor (MPC-150-IM) in Patients with Chronic Heart Failure

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Oct 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Oct 2021 According to a Mesoblast media release, results of this trial have been selected through peer review as a late breaking presentation at the American Heart Association (AHA) annual meeting.
19 Feb 2019 According to a Mesoblast media release,the last patient has been dosed in the trial.
07 Jan 2019 According to a Mesoblast media release, Dr Emerson Perin (Medical Director of Texas Heart Institute and Director of its Stem Cell Center) is the trials co-principal investigator.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com